ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
33 announcements with these filters
Cohance Lifesciences approved the appointment of Mr. Umang Vohra as Chairman and Group CEO, succeeding Mr. Vivek Sharma who resigned effective April 30, 2026. The Board also approved the 'Cohance Lifesciences Limited – Employee Stock Option Plan, 2026' covering 2.59 crore options. These leadership transitions and incentive plans are subject to shareholder approval via postal ballot.
Cohance Lifesciences Limited clarified that recent increases in share trading volume are purely market-driven. The company confirmed there is no undisclosed price-sensitive information or pending announcements that could impact trading behaviour. All regulatory disclosures under SEBI Listing Regulations remain up to date.
Cohance Lifesciences Limited clarified that the recent increase in share trading volume is purely market-driven and attributable to prevailing conditions. The company confirmed there is no pending undisclosed price-sensitive information. All regulatory disclosures under SEBI Listing Regulations are up to date, ensuring transparency for investors regarding the scrip's behavior.